Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
SENOLYTIC AND ANTIINFLAMMATORY PRODRUGS AND METHODS OF USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/057840
Kind Code:
A1
Abstract:
Senolytic and anti-inflammatory prodrugs are provided, which are designed from a cytotoxic agent, by chemically modifying the cytotoxic agent to incorporate a site cleavable by SA-β-gal following delivery of the prodrug in vivo, to release the active parent drug. The prodrug includes a galactose-based moiety, which is preferably acetylated, and benzyl oxy carboxy group and a cytotoxic agent moiety. The selenolytic prodrug is used to selectively kill one or more senescent cells and/or reduce an acute or chronic inflammatory response in a subject in need thereof, by administering to the subject therapeutically effective amount of the senolytic prodrugs. The compositions can be used to reduce one or more symptoms associated with a Senescence -associated disease or disorder or an inflammatory disorder, for example, a virus-mediated inflammation, in a subject.

Inventors:
DENG HONGKUI (CN)
LUO TUOPING (CN)
CAI YUSHENG (CN)
ZHOU HUANHUAN (CN)
ZHU YINHUA (CN)
ZHAO JINGJING (CN)
DONG JIEBIN (CN)
LI HONGGANG (CN)
Application Number:
PCT/CN2020/117386
Publication Date:
April 01, 2021
Filing Date:
September 24, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV BEIJING (CN)
International Classes:
C07H19/073; A61K31/7068; A61P29/00; A61P39/00
Domestic Patent References:
WO2017189553A12017-11-02
WO2009016647A12009-02-05
Foreign References:
US5561119A1996-10-01
US20180094015A12018-04-05
Other References:
GHOSH, A. K. ET AL.: "A daunorubicin β-galactoside prodrug for use in conjunction with gene-directed enzyme prodrug therapy.", TETRAHEDRON LETTERS., vol. 41, 31 December 2000 (2000-12-31), pages 4871 - 4874, XP004205673
SHARMA, A. ET AL.: "Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation.", BIOMATERIALS., vol. 155, 20 November 2017 (2017-11-20), pages 145 - 151, XP085320144
KAMAL, A. ET AL.: "Development of pyrrolo[2,1-c] [1,4] benzodiazepine β-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT.", CHEMMEDCHEM., vol. 3, 5 February 2008 (2008-02-05), pages 794 - 802, XP002651397, DOI: 20201207154348X
HANTHO JOSEPH D., STRAYER TIMOTHY A., NIELSEN AMY E., MANCINI ROCK J.: "An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy", CHEM.MED.CHEM, WILEY-VCH, DE, vol. 11, no. 22, 11 October 2016 (2016-10-11), DE, pages 2496 - 2500, XP055793846, ISSN: 1860-7179, DOI: 10.1002/cmdc.201600443
HEIKO J. SCHUSTER, BIRGIT KREWER, J. MARIAN VON HOF, KIANGA SCHMUCK, INGRID SCHUBERTH, FRAUKE ALVES, LUTZ F. TIETZE: "Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity", ORGANIC & BIOMOLECULAR CHEMISTRY, ROYAL SOCIETY OF CHEMISTRY, vol. 8, no. 8, 17 February 2010 (2010-02-17), pages 1833 - 1842, XP055019053, ISSN: 1477-0520, DOI: 10.1039/b925070k
SARKAR, A.K. ET AL.: "Disaccharide uptake and priming in animal cells: Inhibition of sialyl Lewis X by acetylated Galβ1-4G1cNAcβ-O-naphthalenemethanol Proc.", NATL. ACAD. SCI.USA., vol. 92, 30 April 1995 (1995-04-30), pages 3323 - 3327, XP055793938
Attorney, Agent or Firm:
CHINA SCIENCE PATENT & TRADEMARK AGENT LTD. (CN)
Download PDF: